Dizal (Jiangsu) Pharmaceutical Co., Ltd.

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

Dizal (Jiangsu) Pharmaceutical Co., Ltd. has grabbed the world’s first approval, in China, for a Janus kinase 1 (JAK1) inhibitor for the treatment of relapsed or refractory (r/r) peripheral T-cell ly